cell-free DNA

Geneseeq’s CanScan® test demonstrated 93 percent early-stage detection and a 98 percent specificity rate in a 3,700-person cohort

First multicenter study of cell-free RNA and DNA methylation biomarkers in seminal fluid shows promise for accurate, noninvasive detection of clinically significant prostate cancer

The liquid biopsy market is expected to increase by approximately 20 percent between 2022 and 2032

Integrating epigenetic insights into cancer research could help deliver personalized, high-quality, and cost-effective patient care

The Plasma Detect™ is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer

Liquid biopsy helps screen for ctDNA, which is linked to how patients respond to immuno- and chemo-therapy ​

The innovative approach could help clinicians identify cancer in patients sooner and using smaller blood draws

Join Today's Clinical Lab and Nicole Coufal, MD, PhD, to discuss the single blood test diagnosing multiple infections in pediatric patients

A recently-published review found that NIPS tests accurately detect common genetic conditions in general-risk pregnancies